|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effects of sleeve gastrectomy in high fat diet-induced obese mice: respective role of reduced caloric intake, white adipose tissue inflammation and changes in adipose tissue and ectopic fat depots显示文摘 | Anne-Sophie Schneck Antonio Iannelli Stéphanie Patouraux Déborah Rousseau Stéphanie Bonnafous Beatrice Bailly-Maitre Ophélia Thuc Carole Rovere Patricia Panaia-Ferrari Rodolphe Anty Albert Tran Philippe Gual Jean Gugenheim | 2014 | Surgical Endoscopy2014，，2： | 1 |
| 2 | Identification of Adipose Tissue Dendritic Cells Correlated With Obesity-Associated Insulin-Resistance and Inducing Th17 Responses in Mice and Patients显示文摘 | Adeline Bertola Thomas Ciucci Déborah Rousseau Virginie Bourlier Carine Duffaut Stéphanie Bonnafous Claudine Blin-Wakkach Rodolphe Anty Antonio Iannelli Jean Gugenheim Albert Tran Anne Bouloumié Philippe Gual Abdelilah Wakkach | 2012 | Diabetes2012，，9： | 1 |
| 3 | Increased Adipose Tissue Expression of Hepcidin in Severe Obesity Is Independent From Diabetes and NASH显示文摘 | Soumeya Bekri Philippe Gual Rodolphe Anty Nathalie Luciani Monsef Dahman Bala Ramesh Antonio Iannelli Aline Staccini–Myx Dominique Casanova Imed Ben Amor Marie–Christine Saint–Paul Pierre–Michel Huet Jean–Louis Sadoul Jean Gugenheim Surjit Kaila S. Srai A | 2006 | Gastroenterology2006，，3： | 1 |
| 4 | Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses显示文摘 | Rodolphe Anty Eve Gelsi Jean Giudicelli Eugenia Mariné-Barjoan Philippe Gual Sylvia Benzaken Marie-Christine Saint-Paul Jean Louis Sadoul Pierre Michel Huet Albert Tran | 2007 | European Journal of Gastroenterology & Hepatology2007，，8： | 1 |
| 5 | Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: A randomized controlled trial显示文摘 | Jean Marc Perarnau Amélie Le Gouge Charlotte Nicolas Louis d’Alteroche Patrick Borentain Faouzi Saliba Anne Minello Rodolphe Anty Carine Chagneau-Derrode Pierre Henri Bernard Armand Abergel Isabelle Ollivier-Hourmand Jérome Gournay Jean Ayoub Christophe G | 2014 | Journal of Hepatology2014，，： | 1 |
| 6 | Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib:Multicenter French clinical experience in real-life after matching显示文摘BACKGROUND Starting a second-line systemic treatment for hepatocellular carcinoma(HCC)is a common situation.The only therapeutic options in France are two broadspectrum tyrosine kinase inhibitors(TKIs),regorafenib(REG)and cabozantinib(CBZ),but no comparative real-life studies are available.AIM To evaluate the progression-free survival(PFS)of patients treated with REG or CBZ,we investigated the disease control rate(DCR),overall survival(OS),and safety of both drugs.To identify the variables associated with disease progression over time.METHODS A retrospective multicenter study was performed on the clinical data of patients attending one of three referral centers(Avignon,Marseille,and Nice)between January 2017 and March 2021 using propensity score matching.PFS and OS were assessed using the Kaplan-Meier method.Multivariate analysis(MA)of progression risk factors over time was performed in matched-pair groups.RESULTS Fifty-eight patients 68(62-74)years old with HCC,Barcelona clinic liver cancer(BCLC)B/C(86%),Child-Pugh(CP)-A/B(24%)received REG for 3.4(1.4-10.5)mo as second-line therapy.Twentyeight patients 68(60-73)years,BCLC B/C(75%),CP-A/B(25%)received CBZ for 3.7(1.8-4.9)mo after first-line treatment with sorafenib[3(2-4)(CBZ)vs 4(2.9-11.8)mo(REG),P=0.0226].Twenty percent of patients received third-line therapy.After matching,PFS and DCR were not significantly different after a median follow-up of 6.2(2.7-11.7)mo(REG)vs 5.2(4-7.2)mo(CBZ),P=0.6925.There was no difference in grade 3/4 toxicities,dose reductions,or interruptions.The OS of CP-A patients was 8.3(5.2-24.8)vs 4.9(1.6-11.7)mo(CP-B),P=0.0468.The MA of risk factors for progression over time identified C-reactive protein(CRP)>10 mg/L,neutrophil-to-lymphocyte ratio(NLR)>3,and aspartate aminotransferase(AST)>45 IU as predictive factors.CONCLUSION This multicenter indirect comparative study found no significant difference in PFS between REG and CBZ as second-line therapy for advanced HCC.Elevated levels of inflammatory markers(CRP and NLR)and AST were associated with non-control of TKIs over time.A 2-mo online progression risk calculation is proposed. | Xavier Adhoute Marie De Matharel Laurent Mineur Guillaume Pénaranda Dann Ouizeman Clemence Toullec Albert Tran Paul Castellani Armelle Rollet Valérie Oules HervéPerrier Si Nafa Si Ahmed Marc Bourliere Rodolphe Anty | 2022 | World Journal of Gastrointestinal Oncology2022，14，8： | 0 |
| 7 | Expected outcomes and patients’selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict”scores may help clinicians:Real-life French cohorts results显示文摘BACKGROUND Careful selection of hepatocellular carcinoma(HCC)patients prior to chemoembolization treatment is a daily reality,and is even more necessary with new available therapeutic options in HCC.To propose two new models to better stratify patients and maximize clinical benefit:“6 and 12”and“pre/post-TACE-predict”(TACE,transarterial chemoembolization).METHODS We evaluated and compared their performance in predicting overall survival with other systems{Barcelona Clinic Liver Cancer(BCLC),Albumin-Bilirubin(ALBI)and NIACE[Number of tumor(s),Infiltrative HCC,alpha-fetoprotein,Child-Pugh(CP),and performance status]}in two HCC French cohorts of different stages enrolled between 2010 and 2018.RESULTS The cohorts included 324 patients classified as BCLC stages A/B(cohort 1)and 137 patients classified as BCLC stages B/C(cohort 2).The majority of the patients had cirrhosis with preserved liver function.“Pre-TACE-predict”and“6 and 12”models identified three distinct categories of patients exhibiting different prognosis in cohort 1.However,their prognostic value was no better than the BCLC system or NIACE score.Liver function based on CP and ALBI grades significantly impacted patient survival.Conversely,the“post-TACE-predict”model had a higher predictive value than other models.The stratification ability as well as predictive performance of these new models in an intermediate/advanced stage population was less efficient(cohort 2).CONCLUSION The newly proposed“Pre-TACE-predict”and“6 and 12”models offer an interesting stratification into three categories in a recommended TACE population,as they identify poor candidates,those with partial control and durable response.The models'contribution was reduced in a population with advanced stage HCCs. | Xavier Adhoute Edouard Larrey Rodolphe Anty Patrick Chevallier Guillaume Penaranda Albert Tran Jean-Pierre Bronowicki Jean-Luc Raoul Paul Castellani HervéPerrier Olivier Bayle Olivier Monnet Bernard Pol Marc Bourliere | 2021 | World Journal of Clinical Cases2021，9，18： | 0 |
| 8 | Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma:Real-life Data on Liver Disease,Treatment and Prognosis显示文摘Background and Aims:Hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(iCCA)have common features and differences.This real-life study investigated their characteristics,treatment modalities,and prognoses.Methods:This retrospective comparative study was performed in 1,075 patients seen at one tertiary center between January 2008 and December 2020.Overall survival(OS)was estimated by the Kaplan-Meier method.Subclassification of iCCAs after histological and radiological review,and molecular profiling was performed.Results:HCCs patients were more likely to have early-stage disease than iCCA patients.iCCA patients were more likely to be female,especially those patients without cirrhosis(43%vs.17%).Cirrhosis was prominent among HCC patients(89%vs.34%),but no difference in underlying liver disease among cirrhotic patients was found.OS of HCC patients was 18.4(95%CI:6.4,48.3)months,that of iCCA patients was 7.0(95%CI:3.4,20.1)months.OS of Barcelona Clinic Liver Cancer C HCC patients was 7.8(95%CI:4.3,14.2)months,that of advanced/metastatic iCCA patients was 8.5(95%CI:5.7,12.3)months.In patients treated with sorafenib,OS was longer in HCC patients who received subsequent tyrosine kinase inhibitor therapies.No significant OS difference was found between iCCA patients with and without cirrhosis or according to histological subtype.A targetable molecular alteration was detected in 50%of the iCCA patients.Conclusions:In this French series,cirrhosis was common in iCCA,which showed etiological factors comparable to those of HCC,implying a distinct oncogenic pathway.Both entities had a dismal prognosis at advanced stages.However,systemic therapies sequencing in HCC and molecular profiling in iCCA offer new insights. | Xavier Adhoute Olivia Pietri Guillaume Pénaranda Thomas Wolf Patrick Beaurain Olivier Monnet Arthur Laquière Justine Bonomini Frédéric Neumann Olivier Levrel Jean-Pascal Buono Xavier Hanna Paul Castellani HervéPerrier Marc Bourliere Rodolphe Anty | 2023 | Journal of Clinical and Translational Hepatology2023，11，5： | 0 |
| 9 | “Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort显示文摘The“six-and-twelve”(6&12)score is a new hepatocellular carcinoma(HCC)prognostic index designed for recommended transarterial chemoembolization(TACE)candidates.Quick and easy to use by the sum of tumor size(cm)and number,this model identifies three groups with different survival time(the sum is≤6;or>6 but≤12;or>12);a survival benefit with TACE can be expected for HCC patients with a score not exceeding twelve.Recently,Wang ZW et al showed that the“6&12”model was the best system correlated with radiological response after the first TACE.Thus,we wanted to assess its survival prediction ability as well as its prognostic value and compared it to other systems(Barcelona Clinic Liver Cancer,Hong Kong Liver Cancer(HKLC)staging,Albumin-Bilirubin grade,tumor nodularity,infiltrative nature of the tumor,alpha-fetoprotein,Child-Pugh class,and Performance Status score,Cancer of the Liver Italian Program,Model to Estimate Survival for HCC scores,up-to-seven criteria)different from Wang ZW et al study in a multicenter French cohort of HCC including only recommended TACE candidates retrospectively enrolled.As previously demonstrated,we show that the'6&12”score can classify survival within this French cohort,with a prognostic value comparable to that of other systems,except HKLC staging.More importantly,the“6&12”score simplicity and ability in patients’stratification outperform other systems for a routine clinical practice. | Xavier Adhoute Guillaume Pénaranda Jean-Luc Raoul Jean-Pierre Bronowicki Rodolphe Anty MarcBourlière | 2020 | World Journal of Hepatology2020，12，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员